Mayne Pharma Updates on Cosette Scheme and FDA Clearance

An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.

Mayne Pharma Group Limited has provided an update regarding its Scheme of Arrangement with Cosette Pharmaceuticals. Despite Cosette’s assertion of a material adverse change, Mayne Pharma has not received a termination notice, and the company remains committed to completing the scheme. Additionally, the FDA has issued a close-out letter confirming that Mayne Pharma has addressed previously identified issues. The company is determined to enforce its rights under the scheme implementation deed and encourages shareholders to participate in the upcoming Scheme Meeting.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.

Average Trading Volume: 910,549

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$400.5M

See more data about MYX stock on TipRanks’ Stock Analysis page.